IFNG and neoplasm: Anti-LRIG1 monoclonal antibodies disrupt the interaction between VISTA and LRIG1, resulting in an increased proliferation of immune cells, increased polarization of M1-type macrophages, and an increase in pro-inflammatory cytokines, particularly IFN-γ, which promotes anti-tumor effects (Figure 2D) (29).